Thought I would pass along this e-mail I received.
Dear Jack Saffell,
This is an update from the Bone Marrow Failure Disease Consortium. The following study is currently recruiting participants. This update provides information such as a study summary, eligibility criteria, and a list of participating center locations. If you are interested in participating in this study or you have more questions, please contact the center nearest to you.
Study Name: 5406 – Mechanism and Response of Thymoglobulin in Patients with Myelodysplastic Syndrome (MDS)
Study Status: Recruiting
For:
# Myelodysplastic Syndromes
Summary:
Myelodysplastic syndrome (MDS) is a heterogeneous disease that is characterized by abnormal hematopoiesis that ranges from low-grade MDS to more aggressive stages that often progress to acute leukemia. The primary objective of this study is to estimate the overall clinical response rate to Thymoglobulin as therapy in patients diagnosed with (MDS) and to determine whether presence of expanded T cell clones has predictive power for hematological response.
Participating Centers and Contact Information
# H. Lee Moffitt Cancer Center and Research Institute (BMFDC) (New)
Tampa, Florida
Principal Investigator: Alan List, MD
Contact Person: Tera Uliano
Office: 813-745-1706
Email: tera.uliano@moffitt.org
# The Penn State Cancer Institute (New)
Hershey, Pennsylvania
Principal Investigator: Thomas Loughran, Jr.
Contact Person: Lynn Ruiz, CPL
Office: 717-531-7377
Email: lruiz@psu.edu
.
